Mirfakhraie Reza, Ardakani Maria Tavakoli, Hajifathali Abbas, Karami Samira, Moshari Mohammad Reza, Hassani Mohammad, Firouz Sahar Mashayekhi, Roshandel Elham
Hematopoietic Stem Cell Research Center, Shahid Beheshti University of Medical Sciences, Tehran, Iran; Department of Medical Genetics, School of Medicine, Shahid Beheshti University of Medical Sciences, Tehran, Iran.
Department of Clinical Pharmacy, School of Pharmacy, Shahid Beheshti University of Medical Sciences, Tehran, Iran.
Transpl Immunol. 2022 Apr;71:101524. doi: 10.1016/j.trim.2021.101524. Epub 2022 Jan 3.
Background Allogeneic hematopoietic stem cell transplantation (Allo-HSCT) has been increasingly used as a therapeutic approach for hematological malignancies. Several potential strategies have been developed for treating or preventing allo-HSCT complications, specifically graft-versus-host disease (GVHD). GVHD could significantly affect the morbidity and mortality of patients after allo-HSCT. Curative treatment and prophylaxis regimens for GVHD could reduce GVHD incidence and improve survival rate. Among these therapeutic strategies, mesenchymal stem cell (MSCs) mediated immunomodulation has been explored widely in clinical trials. MSCs immunomodulation ability in GVHD correlates with the interactions of MSCs with innate and adaptive immune cells. However, signaling pathways responsible for MSCs' impact on GVHD regulation, like JAK/STAT, NOTCH, MAPK/ERK, and NFκβ signaling pathways, have not been clearly described yet. This review aims to illuminate the effect of MSCs-mediated immunomodulation in GVHD management after allo-HSCT representing the role of MSCs therapy on signaling pathways in GVHD. Conclusion MSCs could potentially modulate immune responses, prevent GVHD, and improve survival after allo-HSCT. Previous studies have investigated different signaling pathways' contributions to MSCs immunoregulatory ability. Accordingly, targeting signaling pathways components involved in MSCs related GVHD regulation is proven to be beneficial.
背景 异基因造血干细胞移植（Allo-HSCT）已越来越多地被用作血液系统恶性肿瘤的一种治疗方法。已经开发了几种潜在策略来治疗或预防Allo-HSCT并发症，特别是移植物抗宿主病（GVHD）。GVHD会显著影响Allo-HSCT后患者的发病率和死亡率。GVHD的根治性治疗和预防方案可以降低GVHD的发生率并提高生存率。在这些治疗策略中，间充质干细胞（MSCs）介导的免疫调节已在临床试验中得到广泛探索。MSCs在GVHD中的免疫调节能力与MSCs与先天性和适应性免疫细胞的相互作用有关。然而，负责MSCs对GVHD调节影响的信号通路，如JAK/STAT、NOTCH、MAPK/ERK和NFκβ信号通路，尚未得到明确描述。本综述旨在阐明MSCs介导的免疫调节在Allo-HSCT后GVHD管理中的作用，代表MSCs治疗在GVHD信号通路中的作用。结论 MSCs可能潜在地调节免疫反应，预防GVHD，并提高Allo-HSCT后的生存率。先前的研究已经调查了不同信号通路对MSCs免疫调节能力的贡献。因此，靶向参与MSCs相关GVHD调节的信号通路成分已被证明是有益的。
